recombinant human tissue kallikrein

Sponsor Diamedica Therapeutics INC. · listed as DMAC

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

recombinant human tissue kallikrein is a clinical-stage drug asset sponsored by Diamedica Therapeutics INC., listed as DMAC. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT05065216. The asset is in Phase 2;Phase 3 and currently recruiting, studied in Acute Stroke.

Next catalyst

Event typeREADOUT

Expected date2026-12-31

As disclosedDec 2026

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT05065216

PhasePHASE2;PHASE3

StatusRECRUITING

Lead sponsorDiaMedica Therapeutics Inc

Listed asDMAC

Condition(s)Acute Stroke; Ischemic Stroke; Stroke

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More DMAC catalysts